HIV coinfection with hepatitis c overview

HIV coinfection with hepatitis c Microchapters

Home

Patient Information

Overview

Pathophysiology

Causes

Differentiating HIV coinfection with hepatitis c from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Treatment

Medical Therapy

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

HIV coinfection with hepatitis c overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of HIV coinfection with hepatitis c overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on HIV coinfection with hepatitis c overview

CDC on HIV coinfection with hepatitis c overview

HIV coinfection with hepatitis c overview in the news

Blogs on HIV coinfection with hepatitis c overview

Directions to Hospitals Treating HIV coinfection with hepatitis c

Risk calculators and risk factors for HIV coinfection with hepatitis c overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

## Overview[edit | edit source]

HIV has been an important and familiar health and social crisis for two decades. Less familiar, but also important, is HCV infection. In HIV–HCV co-infected patients, the Hepatitis C (HCV) viral load is higher than in HCV-mono-infected patients in both the plasma and liver tissue.

Similarity between Hepatitis C with HIV: These two viruses are similar in a number of ways, and infection with both is a serious problem. Both HCV and HIV are transmitted by exposure to infected blood. About one-quarter of the people infected with HIV also have HCV.

## Treatment[edit | edit source]

### Medical Therapy[edit | edit source]

The primary objective of HCV therapy is permanent eradication of the virus. The secondary potential benefit of eradication is a reduction in the risk of liver failure and liver cancer.

The introduction in the mid-1990s of highly active antiretroviral therapy (HAART) for HIV has caused a sharp drop in the number of deaths from AIDS. This means that people with HIV are living longer. Therefore, if they are co-infected, the complications from HCV have more time to develop. These complications (cirrhosis, liver cancer, end-stage liver disease) generally develop over 20-30 years.

Liver disease from HCV is now the leading non-AIDS cause of death in the U.S. in co-infected individuals with HIV. Treatment for each disease is complicated, expensive, and has side effects. This poses difficult issues for patients who are living with both HIV and HCV. Finally, co-infection is important because it has a disproportionate impact on certain communities, including those in prison and jail and communities of color.

## References[edit | edit source]